Evidence map›Paper›PMID 26965143›Full record

ArticleMolecular cancer research : MCR2016

Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.

Rebecca A Frum, Ian M Love, Priyadarshan K Damle, Nitai D Mukhopadhyay, Swati Palit Deb, Sumitra Deb, Steven R Grossman

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Mutant p53 as a guardian of the cancer cell.Cell death and differentiation · 2019
    Review
  7. Review
  8. Article
  9. There and Back Again: The Middle Earth of DNA Repair.Molecular cancer research : MCR · 2016
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rebecca A FrumDivision of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University, Richmond, Virginia.
Ian M LoveDivision of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University, Richmond, Virginia.
Priyadarshan K DamleDivision of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University, Richmond, Virginia.
Nitai D MukhopadhyayDepartment of Biostatistics, Virginia Commonwealth University, Richmond, Virginia.
Swati Palit DebDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia. VCU Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
Sumitra DebDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia. VCU Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
Steven R GrossmanDivision of Hematology, Oncology, and Palliative Care, Virginia Commonwealth University, Richmond, Virginia. VCU Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. steven.grossman@vcuhealth.org.
Virginia Commonwealth University · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
Role of p300/CBP and hHR23 Proteins in p53 RegulationR01CA107532 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GROSSMAN, STEVEN R. · 2004 to 2014
$2.6M
Chemoresistance and Motility: Role of Mutant p53 and NF-kB2 in CancerR01CA121144 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DEB, SUMITRA · 2008 to 2011
$1.0M
NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA107532NCI NIH HHS R01 CA121144
6 · The paper itself

Abstract

unlabelledMany mutant p53 proteins exhibit an abnormally long half-life and overall increased abundance compared with wild-type p53 in tumors, contributing to mutant p53's gain-of-function oncogenic properties. Here, a novel mechanism is revealed for the maintenance of mutant p53 abundance in cancer that is dependent on DNA damage checkpoint activation. High-level mutant p53 expression in lung cancer cells was associated with preferential p53 monoubiquitination versus polyubiquitination, suggesting a role for the ubiquitin/proteasome system in regulation of mutant p53 abundance in cancer cells. Interestingly, mutant p53 ubiquitination status was regulated by ataxia-telangectasia mutated (ATM) activation and downstream phosphorylation of mutant p53 (serine 15), both in resting and in genotoxin-treated lung cancer cells. Specifically, either inhibition of ATM with caffeine or mutation of p53 (serine 15 to alanine) restored MDM2-dependent polyubiquitination of otherwise monoubiquitinated mutant p53. Caffeine treatment rescued MDM2-dependent proteasome degradation of mutant p53 in cells exhibiting active DNA damage signaling, and ATM knockdown phenocopied the caffeine effect. Importantly, in cells analyzed individually by flow cytometry, p53 levels were highest in cells exhibiting the greatest levels of DNA damage response, and interference with DNA damage signaling preferentially decreased the relative percentage of cells in a population with the highest levels of mutant p53. These data demonstrate that active DNA damage signaling contributes to high levels of mutant p53 via modulation of ubiquitin/proteasome activity toward p53. IMPLICATION: The ability of DNA damage checkpoint signaling to mediate accumulation of mutant p53 suggests that targeting this signaling pathway may provide therapeutic gain. Mol Cancer Res; 14(5); 423-36. ©2016 AACR.

Indexed as

MutationAtaxia Telangiectasia Mutated ProteinsCell Line, TumorDNA DamageGene Expression Regulation, NeoplasticGenes, cdcHalf-LifeHumansLung NeoplasmsPhosphorylationProteasome Endopeptidase ComplexProto-Oncogene Proteins c-mdm2SerineTumor Suppressor Protein p53UbiquitinationAtaxia Telangiectasia Mutated ProteinsATM protein, humanMDM2 protein, humanProteasome Endopeptidase ComplexProto-Oncogene Proteins c-mdm2SerineTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID26965143
PMCPMC5110038
OpenAlexW2295691350

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.